CYP2C19pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials

MLA

Babikir Kheiri, et al. “CYP2C19pharmacogenetics versus Standard of Care Dosing for Selecting Antiplatelet Therapy in Patients with Coronary Artery Disease: A Meta-Analysis of Randomized Clinical Trials.” Catheterization and Cardiovascular Interventions, vol. 93, Nov. 2018, pp. 1246–52. EBSCOhost, https://doi.org/10.1002/ccd.27949.

APA

Babikir Kheiri, Ahmed Abdalla, Tarek Haykal, Pranay Pandrangi, Mohammed Osman, Mustafa Hassan, Deepak L. Bhatt, Ghassan Bachuwa, Adam Chahine, Khansa Osman, & Sahar Ahmed. (2018). CYP2C19pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials. Catheterization and Cardiovascular Interventions, 93, 1246–1252. https://doi.org/10.1002/ccd.27949

Chicago

Babikir Kheiri, Ahmed Abdalla, Tarek Haykal, Pranay Pandrangi, Mohammed Osman, Mustafa Hassan, Deepak L. Bhatt, et al. 2018. “CYP2C19pharmacogenetics versus Standard of Care Dosing for Selecting Antiplatelet Therapy in Patients with Coronary Artery Disease: A Meta-Analysis of Randomized Clinical Trials.” Catheterization and Cardiovascular Interventions 93 (November): 1246–52. doi:10.1002/ccd.27949.